Xenon Pharmaceuticals Inc (XENE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xenon Pharmaceuticals Inc (XENE) has a cash flow conversion efficiency ratio of -0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-81.48 Million) by net assets ($581.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Xenon Pharmaceuticals Inc (XENE) net asset quality to measure how much of total assets are equity-financed.
Xenon Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Xenon Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check XENE operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Xenon Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xenon Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningxia Orient Tantalum Industry Co Ltd
SHE:000962
|
-0.065x |
|
Daeduck Electronics Co Ltd
KO:353200
|
0.061x |
|
Tegna Inc
NYSE:TGNA
|
0.034x |
|
Jiangxi Jovo Energy Co. Ltd
SHG:605090
|
-0.003x |
|
Hubei Zhenhua Chemical Co Ltd
SHG:603067
|
0.013x |
|
HBIS Co Ltd
SHE:000709
|
0.053x |
|
Hang Zhou Iron & Steel Co Ltd
SHG:600126
|
0.124x |
|
JUMBO SA UNSP.ADR/1 O.N.
F:5JB1
|
N/A |
Annual Cash Flow Conversion Efficiency for Xenon Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Xenon Pharmaceuticals Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see XENE stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $581.76 Million | $-279.12 Million | -0.480x | -99.68% |
| 2024-12-31 | $754.90 Million | $-181.39 Million | -0.240x | -53.42% |
| 2023-12-31 | $927.92 Million | $-145.33 Million | -0.157x | -14.80% |
| 2022-12-31 | $721.50 Million | $-98.43 Million | -0.136x | -7.97% |
| 2021-12-31 | $550.03 Million | $-69.50 Million | -0.126x | +55.01% |
| 2020-12-31 | $171.35 Million | $-48.12 Million | -0.281x | -457.67% |
| 2019-12-31 | $91.98 Million | $-4.63 Million | -0.050x | +85.02% |
| 2018-12-31 | $103.30 Million | $-34.72 Million | -0.336x | +57.95% |
| 2017-12-31 | $35.93 Million | $-28.73 Million | -0.799x | -161.07% |
| 2016-12-31 | $63.90 Million | $-19.57 Million | -0.306x | -3.24% |
| 2015-12-31 | $61.03 Million | $-18.10 Million | -0.297x | -8215.27% |
| 2014-12-31 | $72.78 Million | $266.00K | 0.004x | +102.65% |
| 2013-12-31 | $24.12 Million | $-3.32 Million | -0.138x | -103.82% |
| 2012-12-31 | $12.62 Million | $45.57 Million | 3.610x | -- |
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizure… Read more